Purity and Quality Guaranteed:
Lubrisine Eye Drops is produced under strict GMP manufacturing controls in conformance with guidelines for dietary supplements set forth in USP XXVII. For purity and quality, Lubrisine Eye Drops contains no preservatives • no artificial coloring or flavoring. For customer support, please call 1 888 823 3869.
Directions:
Instill 1 or 2 drops in the affected eye(s) as needed.
Warnings:
If the solution becomes contaminated do not use. To avoid contamination, do not touch tip of container to any surface. Replace cap after using.
Ingredients
Vitamin A (from Palmitate and Mixed Carotenoids), Lutein (Natural Lutein Esters), Bilberry (Vaccinium myrtillus) (fruit), Burdock Root (Arctium lappa), Eyebright Herb (Euphrasia officinalis), Blessed Thistle Herb (Cnicus benedicts), Angelica Root (Angelica archangelica), Devil’s Claw Root (Harpagophytum procumbens), Natural Trace Minerals, PEG 400 0.4%, Propylene glycol 0.3% in Ultra-Pure Deionized Water.
* % Daily value not established
For Best Results:
Take Results RNA Lubrisine Eye Drops with ACS 200 Extra Strength and ACZ Nano Extra Strength to achieve enhanced allergy season relief and total body detoxification.
RESEARCH AND SUMMARY COMMENTS
LUBRISINE EYE DROPS
Ingredients:
Vitamin A (from Palmitate and Mixed Carotenoids), Lutein (Natural Lutein Esters), Bilberry (Vaccinium myrtillus) (fruit), Burdock Root (Arctium lappa), Eyebright Herb (Euphrasia officinalis), Blessed Thistle Herb (Cnicus benedicts), Angelica Root (Angelica archangelica), Devil’s Claw Root (Harpagophytum procumbens)
VITAMIN A (FROM PALMITATE AND MIXED CAROTENOIDS)
1. A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome.
The purpose of the study was to compare the efficacy of vitamin A (retinyl palmitate) and cyclosporine A 0.05% eye drops in treating patients with dry eye disease.
A total of 150 patients with defined dry eye disease participated (50 in each treatment group). In 3 identical clinical trials, patients were treated twice daily with cyclosporine A 0.05%, or four times daily with retinyl palmitate 0.05%, or with neither cyclosporine or retinyl palmitate. Adjunctive treatment with preservative-free artificial tears was undertaken four times daily in all 3 groups. Corneal fluorescein staining results, Schirmer tear test (without anesthesia) results, tear film break-up time (BUT), dry eye symptom score, and impression cytologic analysis results were obtained before treatment and at the first, second, and third months after initiation of treatment.
Both vitamin A eye drops and topical cyclosporine A 0.05% treatments led to significant improvement in blurred vision, tear film BUT, Schirmer I score results, and impression cytologic findings in patients with dry eye syndrome (P < .05) compared to the control group treated with preservative-free artificial tears alone. Takeaway:
• Vitamin A drops are effective for the treatment of dry eye and blurred vision.
LUTEIN (NATURAL LUTEIN ESTERS)
2. Lutein acts via multiple antioxidant pathways in the photo-stressed retina.
Lutein slows the progression of age-related macular degeneration (AMD), a leading cause of blindness in ageing societies. However, the underlying mechanisms remain elusive. Here, we evaluated lutein’s effects on light-induced AMD-related pathological events. Balb/c mice exposed to light (2000 lux, 3 h) showed tight junction disruption in the retinal pigment epithelium (RPE) at 12 h, as detected by zona occludens-1 immunostaining.
Substantial disruption remained 48 h after light exposure in the vehicle-treated group; however, this was ameliorated in the mice treated with intraperitoneal lutein at 12 h, suggesting that lutein promoted tight junction repair. In the photo-stressed RPE and the neighboring choroid tissue, lutein suppressed reactive oxygen species and increased superoxide dismutase (SOD) activity at 24 h, and produced sustained increases in sod1 and sod2 mRNA levels at 48 h.
Takeaway:
• These findings indicated that lutein promoted tight junction repair and suppressed inflammation in photo-stressed mice, supporting previous findings that lutein is effective in slowing the progression of AMD.
BILBERRY (VACCINIUM MYRTILLUS) (FRUIT)
3. Bilberry extract supplementation for preventing eye fatigue in video display terminal workers.
The purpose of the study was to examine the effect of a dietary supplement containing bilberry extract (BE) on eye fatigue induced by acute video display terminal (VDT) loads.
Two hundred eighty-one office workers aged 20-40 years that used VDTs were screened by critical flicker fusion (CFF) and near point accommodation (NPA). The participants were randomized to either a BE (480 mg/day) or placebo (vehicle) group, and took allocated capsule, daily, for 8 weeks.
The CFF, NPA, contrast visual acuity, functional visual acuity, keratoconjunctival epithelial damage, and fluorescein tear film break-up time were examined, and 18 subjective symptoms of eye fatigue were evaluated by questionnaire. Adverse events were reported via medical interviews. Data were collected both before and after VDT load at baseline, and 4, and 8 weeks after daily supplementation with either BE or placebo.
The VDT load-induced reduction in CFF was alleviated after 8 weeks of BE supplementation (95% confidence interval, 0.10-1.60; p=0.023), in contrast to placebo supplementation, while NPA variation was not. Of the subjective symptoms of eye fatigue, VDT load-induced ocular fatigue sensation, ocular pain, eye heaviness, uncomfortable sensation, and foreign body sensation were mitigated more in the BE group than in the control group, at week 8 (p<0.05). There were no severe adverse events in either group. Takeaway:
Bilberry supplementation improved objective and subjective parameters of eye fatigue.
EYEBRIGHT HERB (EUPHRASIA OFFICINALIS)
4. Assessment of Eyebright (Euphrasia Officinalis L.) Extract Activity in Relation to Human Corneal Cells Using In Vitro Tests
Euphrasia officinalis L. is an herb traditionally used in folk medicine, mainly in the treatment of eye disorders.
The present study analyzed the activity of three extracts of E. officinalis L. (ethanol, ethyl acetate and heptane) on cultured human corneal epithelial cells (10.014 pRSV-T).
We show that the biological effect depended on both the concentration and the extraction solvent used. Heptane extracts, distinct from those in ethanol and ethyl acetate, were toxic to 10.014 pRSV-T cells at low concentrations (25 μg/mL) and did not demonstrate free radical scavenging effects. All tested extracts decreased pro-inflammatory cytokine expression (IL-1β, IL-6 and TNF-α) and also anti-inflammatory IL-10 expression by human corneal cells when the extracts were added to the cell culture medium for 24 h.
Takeaway:
E. officinalis L. shows promise as a supplementary therapy for eye inflammation (conjunctivitis) and irritated eyes.
Citation links:
1. https://www.ncbi.nlm.nih.gov/pubmed/18848318
2. https://www.ncbi.nlm.nih.gov/pubmed/27444056
3. https://www.ncbi.nlm.nih.gov/pubmed/25923485
4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4115993/